Specialists in drug discovery and developme...( More than 2500 researchers and profe...),Health

More than 2,500 researchers and professionals in the area of biomolecular science and drug discovery are expected to attend the 14th Annual Conference & Exhibition of the Society for Biomolecular Sciences (SBS) April 6-10, in St. Louis at Americas Center to discuss advances in biotechnology, challenges and automation solutions in the field.

Highlights of topics and speakers at this years meeting include:

• New Methods of Tracking Target Molecules -- Jeremy Caldwell, Ph.D., director of molecular and cell biology, Genomics Institute, Novartis Research Foundation, will conduct a panel discussion about the latest in drug therapies as used to target molecules associated with rare and orphan diseases. Through these new targets and applied technologies, therapies once thought to be impossible in major diseases may become available and will assist in the pursuit of therapies for the eradication of neglected diseases. Research to be presented includes RNA interference as a more effective way to help the body quickly respond to infectious and viral diseases.

• New Trends in Pharmaceutical and Academic Collaborations -- A panel of National Institutes of Health and some of the worlds leading academic researchers will discuss the need for universities and non-profit institutes across the U.S. to increase their collaborative efforts with the pharmaceutical industry by applying their research findings to drug discovery for diseases pharmaceutical companies cant address on their own. As the pharmaceutical industry focuses on late stage drug development to get more effective medications to market, greater partnerships are necessary between academic and pharmaceutical researchers to discover more of the underlying causes for diseases. The panelists also are part of an increasing trend of more researchers segueing from the pharmaceutical industry to academic environments where there are fewer research constraints.
  '/>"/>